SKLB1028 clinical trials
Also written SKLB1028.
How each study uses SKLB1028 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SKLB1028 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SKLB1028
- 6
Studies by the year they started
9 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses SKLB1028 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05445154Written as SKLB1028 Dose EscalationHow we know
- A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-MutatedRecruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04716114Written as SKLB1028How we know
- A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male SubjectsCompletedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05369858Written as [14C] SKLB1028How we know
- A Dose Escalation and Food Effect Study of SKLB1028 in Healthy SubjectsCompletedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05109663Written as SKLB1028How we know
- A Study of SKLB1028 in Patients With Advanced Solid TumorStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05072522Written as SKLB1028How we know
- A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy SubjectsCompletedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05070195Written as SKLB1028How we know
- A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy SubjectsStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05069870Written as SKLB1028How we know
- A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML PatientsStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04015024Written as SKLB1028 150mg bidHow we know
- A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT02859948Written as SKLB1028How we know